AiViva Biopharma Appoints Jung-Chin (Rongjin) Lin, to the Board of Directors

COSTA MESA, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company developing innovative therapies to address major unmet medical needs, today announced the appointment of Mr. Jung-Chin (Rongjin) Lin to its board of directors. He is Honorary President of Center Laboratories, Inc. and Chairman of the Board of Lumosa Therapeutics Co., Ltd. and Glac Biotech Co., Ltd. He also serves as a Board member at Adimmune Corp. and BioGend Therapeutics Co., Ltd

Related Keywords

Hong Kong ,United States ,Australia ,Taiwan ,China ,Taipei ,T Ai Pei ,Aiviva Biopharma ,Jung Chin Rongjin Lin ,Diane Tang Liu ,Adimmune Corp ,Aiviva Holding ,Pharmaengine Inc ,Aiviva Biopharma Inc ,Medeon Biodesign Inc ,Center Laboratories Inc ,Board Of Mycenax Biotech Inc ,Biogend Therapeutics Co Ltd ,Board Of Lumosa Therapeutics Co Ltd ,Taipei Medical University ,Glac Biotech Co Ltd ,Viva Biopharma Inc ,Honorary President ,Center Laboratories ,Mycenax Biotech ,Medeon Biodesign ,Honoris Causa ,Aiviva Holding Limited ,Viva Biopharma ,Nc ,In ,Lac Biotech Co ,Harmaengine ,Iopharma ,Biotechnology Company ,